Objective. An increasing number of patients with prostate cancer develop hormone-refractory disease after standard treatment modalities. In these patients, early clinical trials with chemotherapy produced disappointing response rates. However, clinical trials that employ response criteria such as prostate-specific antigen (PSA) and clinical benefit response have produced encouraging responses. This article reviews current and future treatment options for the management of hormone-refractory prostate cancer.
Data Sources. A MEDLINE search for the years 1978 to 1998 was completed. The following terms were used in our search: prostate cancer, hormone-refractory, treatment, and chemotherapy. Relevant articles referenced in the literature obtained in our MEDLINE search were reviewed.
Study Selection. Randomized and nonrandomized clinical trials were used in our review. Clinical trials using prostate-specific antigen or a palliation of symptoms as primary criteria for response were given priority.
Data Synthesis. Several genetic alterations, including the overexpression of bcl-2 or mutations in p53, may lead to the development of hormone-refractory prostate cancer. Agents such as estramustine and taxanes, which affect microtubule function and potentially modulate bcl-2, appear to be particularly active in the treatment of hormone-refractory prostate cancer. In addition, mitoxantrone as well as other agents has been shown to be beneficial in improving the quality of life in patients with hormone-refractory prostate cancer.
Conclusion. Hormone-refractory prostate cancer is not a chemotherapy-resistant disease as once believed; significant progress in the treatment of hormone-refractory prostate cancer has been made with new combinations of chemotherapy agents. Promising new treatments are currently under evaluation to assess their potential benefit over the standard treatment modalities that are currently available.
Potosky AL, Miller BA, Albertson PC, et al.The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
2.
Silverberg E, Lubera JA.Cancer statistics. CA Cancer J Clin. 1988;38:14-15.
3.
Landis SH, Murray T, Bolden S, et al.Cancer statistics. CA Cancer J Clin. 1998;48:6-30.
4.
Boyle P, La Vecchia C, Maisonneuve P, et al.Cancer epidemiology and prevention. In: Veronesi U, Peckham NJ, Pinedo R, eds. Oxford Textbook of Oncology. Oxford, United Kingdom: Oxford University Press; 1995:219-219.
5.
Hanks GE, Krall JM, Hanlon AL, et al.Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys. 1994;28:39-45.
6.
Zincke H, Oesterling, JE, Blute ML, et al.Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850-1857.
7.
Crawford ED, Eisenberger MA, McLeod DG, et al.A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-424.
8.
Eisenberger MA, Crawford ED, Wolf M, et al.Prognostic factors in stage D2 prostate cancer: important implications for future trials. Results of a cooperative intergroup study (INT 0036). Semin Oncol. 1994;21:613-619.
9.
Scher HI, Mazumdar M, Kelly WK.Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst. 1996;88: 1623-1634.
10.
Labrie F, Dupont A, Belanger A, et al.New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4:579-594.
11.
Denis LJ, Moura JL, Bono A, et al.Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology. 1993;42:119-129.
12.
Iversen P, Rasmussen F, Klarskov P, et al.Long-term results of Danish Prostatic Cancer Group Trial 86. Cancer. 1993;72:3851-3854.
13.
Janknegt RA, Abbou CC, Bartoletti R, et al.Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993; 149:77-83.
14.
Zalcberg JR, Raghaven D, Marshall V, et al.Bilateral orchiectomy and flutamide versus orchiectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate: an Australian multicentre trial. Br J Urol. 1996;77:865-869.
15.
Prostate Cancer Trialists’ Collaborative Group (PCTCG). Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet. 1995;346:265-269.
16.
Caubet JF, Tosteson TD, Dong EW, et al.Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using non-steroidal antiandrogens. Urology. 1997;49:71-78.
17.
Sato N, Gleave ME, Bruchovsky N, et al.Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996;58:139-146.
18.
Grossfield GD, Small EJ, Carroll PR.Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998;51:137-144.
19.
Geller J, Albert J, Vik A.Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol. 1988; 15:53-61.
20.
Kelly WK, Scher HI.Prostate-specific antigen decline after anti-androgen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;3:607-609.
21.
Herrada J, Dieringer P, Logothetis CJ.Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate-specific antigen decreased following flutamide withdrawal. J Urol. 1996;155:620-623.
22.
Nieh PT.Withdrawal phenomenon with the antiandrogen casodex. J Urol. 1995;153:1070-1073.
23.
Akakura K, Akimoto S, Ohki T, et al.Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal anti-androgen chlormadinone acetate. Urology. 1995;45:700-704.
24.
Dawson NA, McLeod DG.Dramatic prostate-specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol. 1995;153:1946-1947.
25.
Gomella LG, Ismail M, Nathan FE.Antiandrogen withdrawal syndrome with nilutamide. J Urol. 1997;157:1366-1366.
26.
Dupont A, Gomez JL, Cusan L, et al.Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993;150:908-913.
27.
Legault-Poisson S, Jolivet J, Poisson R, et al.Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep. 1979;63:1839-1841.
28.
Belani CP, Pearl P, Whitley NO, et al.Tamoxifen withdrawal response: report of a case. Arch Intern Med. 1989;149:449-450.
29.
Taplin ME, Bubley GJ, Shuster TD, et al.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-1398.
30.
Wilding G, Chen M, Gelmann EP.Aberrant response in vitro of hormone responsive prostate cells to antiandrogens. Prostate. 1989;14:103-115.
31.
Veldscholte J, Berrevoets CA, Brinkmann AO, et al.Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry. 1992;31:2393-2299.
32.
Labrie C, Veilleux R, Fournier A.Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J Natl Cancer Inst. 1988;80:1138-1147.
33.
Loose DS, Kan PB, Hirst MA, et al.Ketoconazole blocks steroido-genesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71:1495-1499.
34.
Pont A, Williams PL, Azhar S.Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982;142:2137-2140.
35.
Trachtenberg J, Pont A.Ketoconazole therapy for advanced prostate cancer. Lancet. 1984;2:433-435.
36.
Small EJ, Baron AD, Fippin L, et al.Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997;157:1204-1207.
37.
Tannock I, Gospodarowicz M, Meakin M, et al.Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590-597.
38.
Dawson NA, Cooper MR, Figg WD, et al.Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 1995;76:453-462.
39.
Chang AYC, Bennett JM, Pandya KJ, et al.A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am J Clin Oncol. 1989;12:358-360.
40.
Plowman PN, Perry LA, Chard T.Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br J Urol. 1987;59:255-257.
41.
DeVooght HJ.Second-line treatment in hormone-refractory prostate cancer. In: Schroder FH, Richards B, eds. EORTC GU-Group Monograph 2: Therapeutic Principles in Metastatic Prostate Cancer. New York: Alan R. Liss; 1985:56-56.
42.
Raghavan D, Rogers J.Update in the management of prostate cancer. Med J Aust. 1990;152:419-426.
43.
McDonnell TJ, Troncoso P, Brisbay SM, et al.Expression of the protooncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940-6944.
44.
Oltvai ZN, Milliman CL, Korsmeyer SJ.Bcl-2 heterodimerizes in vivo with a conserved homolog bax, which accelerates programmed cell death. Cell. 1993;74:609-619.
45.
Wright E.Death-defying acts: a meeting review of apoptosis. Genes and Development. 1993;7:2277-2284.
46.
Colombel M, Symmans F, Gil S, et al.Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol. 1993;143:390-400.
47.
Peehl DM, Wehner N, Stamey TA, et al.Activated Ki-ras onco-gene in human prostatic adenocarcinoma. Prostate. 1987;10: 281-289.
48.
Carter BS, Epstein JI, Isaacs WB.ras gene mutations in human prostate cancer. Cancer Res. 1990;50:6830-6832.
49.
Effert PJ, Neubauer A, Walther PJ, et al.Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol. 1992;147:789-793.
50.
Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al.Alteration of the tumor suppressor gene p53 in a high fraction of hormone-refractory prostate cancer. J Urol. 1995;154:414-421.
51.
Bookstein R, Rio P, Madreperla SA, et al.Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA. 1990;87:7762-7766.
52.
Fleming WH, Hamel A, MacDonald R, et al.Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 1986;46:1535-1538.
53.
Tannock IF.Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?J Clin Oncol. 1985;3: 1013-1021.
54.
Gann PH, Hennekens CH, Stampfer MJ.A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA. 1995;273:289-294.
55.
Frazier HA, Robertson JE, Humphrey PA, et al.Is prostate-specific antigen of clinical importance in evaluating outcome after radical prostatectomy?J Urol. 1993;49:516-518.
56.
Lightner DJ, Lange PH, Reddy PK, et al.Prostate-specific antigen and local recurrence after radical prostatectomy. J Urol. 1990; 144:921-926.
Hudson MA, Bahnson RR, Catalona WJ.Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol. 1989; 142:1011-1017.
59.
Ritter MA, Messing EM, Shanahan T, et al.Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 1992;10:1208-1217.
60.
Hudes GR, Greenberg R, Krigel RL, et al.Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992;10:1754-1761.
61.
Kelly WK, Scher HI, Mazumdar M, et al.Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refrac-tory prostate cancer. J Clin Oncol. 1993;11:607-615.
62.
Pienta KJ, Redman B, Hussain M, et al.Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005-2012.
63.
Eisenberger MA, Nelson WG.How much can we rely on the level of prostate-specific antigen as an endpoint for evaluation of clinical trials? A word of caution. J Natl Cancer Inst. 1996;88: 779-781.
64.
Guess HA, Glenn GJ, Stoner E, et al.The effect of finasteride on prostate-specific antigen: review of available data. J Urol. 1996; 155:3-9.
65.
Fields S, Burris H, Wilding G, et al.Evaluating the role of navelbine in hormone-refractory prostate cancer: a clinical benefit model. Proc Am Soc Clin Oncol. 1994;13:727-727.
66.
Rothenberg ML, Moore MJ, Cripps MC, et al.A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353.
67.
Scher HI, Yagoda A.Clinical trials in prostatic cancer: methodology and controversies. In: Bruce AW, Trachtenberg J, eds. Adenocarcinoma of the Prostate. New York: Springer-Verlag; 1987:197-220.
68.
Slack NH, Mittleman A, Brady MF, et al.The importance of the stable category for chemotherapy-treated patients with advanced and relapsing prostate cancer. Cancer. 1980;46:2393-2402.
69.
Yagoda A, Petrylak D.Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
70.
Hartley-Asp B, Kruse E.Nuclear matrix as a target for estramustine-induced cell death. Prostate. 1986;15:387-395.
71.
Pienta KJ, Lehr JE.Inhibition of prostate cancer growth by estramustine and etoposide: evidence for the interaction at the nuclear matrix. J Urol. 1993;149:1622-1625.
72.
Hartley-Asp B.Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines, DU 145 and PC-3. Prostate. 1984;5:93-100.
73.
Yagoda A, Smith JA, Soloway MS, et al.Phase II study of estramustine phosphate in advanced hormone-refractory prostatic cancer with increasing prostate-specific antigen levels. J Urol. 1991;145:384-384.
74.
Iversen P, Rasmussen F, Asmussen C, et al.Estramustine phosphate versus placebo as second-line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol. 1997;157:929-934.
75.
Mareek MM, Storma GA, Dragonett CH, et al.Anti-invasive activity of estramustine and vinblastine on malignant MO4 and on DU 145 human prostate carcinoma cells in vitro. Cancer Res. 1988;48: 1842-1849.
76.
Hudes GR, Nathan FE, Khater C, et al.Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995;22:41-45.
77.
Petrylak DP, Shelton G, Judge T, et al.Phase I trial of docetaxel plus estramustine in androgen-insensitive prostate cancer. Proc Am Soc Clin Oncol. 1997;16:310-310.
78.
Drexus F, Logothetis CJ, Samuels ML, et al.Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep. 1985;69:885-886.
79.
Seidman AD, Scher HI, Petrylak D, et al.Estramustine and vinblastine: use of prostate-specific antigen as a clinical trial endpoint for hormone-refractory prostatic cancer. J Urol. 1992; 147:931-934.
80.
Attivissimo LA, Fetten JV, Kreis W.Symptomatic improvement associated with combined estramustine and vinblastine chemo-therapy for metastatic prostate cancer. Am J Clin Oncol. 1996; 19:581-583.
81.
Pienta KJ, Redman B, Hussain M, et al.Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005-2012.
82.
Pienta KJ, Redman B, Bandekar R, et al.Phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology. 1997;50:401-407.
83.
Scher H, Yagoda A, Watson RC, et al.Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol. 1984;131:1099-1102.
84.
Tarti FM, Aston D, Lum BL, et al.Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol. 1983;1:477-482.
85.
Sella A, Kilbourn R, Amato R, et al.Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 1994;12:683-688.
86.
Small EJ, Srinivas S, Egan B, et al.Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol. 1996;14:1617-1625.
87.
Moore MJ, Osoba D, Murphy K, et al.Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 1994;12:689-694.
88.
Tannock IF, Osoba D, Stockler MR, et al.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol. 1996;14:1756-1764.
89.
Halder S, Chintapalli J, Croce CM.Taxol induces bcl-2 phosphor-ylation and death of prostate cancer cells. J Cancer Res. 1996;56: 1253-1255.
90.
Halder S, Basu A, Croce CM.Bcl-2 is the guardian of microtubule integrity. J Cancer Res. 1997;57:229-233.
91.
Tu S, McConnell K, Marin MC, et al.Combination adriamycin and suramin induces apoptosis in bcl-2-expressing prostate carcinoma cells. Cancer Lett. 1995;93:147-155.
92.
Zhang C, DiPaola RS, White E, et al.Restoration of taxol sensitivity in a p53 mutant, bcl-2-overexpressing cell line by interferon-a and retinoic acid. Proc Am Assoc Cancer Res. 1997;38:3563-3563.
93.
Roth BJ, Yeap BY, Wilding GW, et al.Taxol in advanced hormone-refractory carcinoma of the prostate. Cancer. 1993;72: 2457-2460.
94.
Rowinsky E, Burke P, Karp J, et al.Phase I and pharmacodynamic study of taxol in refractory and acute leukemia. Cancer Res. 1989;49:4640-4647.
95.
Extra JM, Rousseau F, Brano R, et al.Phase I and pharmacokinetic study of taxotere as a short intravenous infusion. Cancer Res. 1993;53:1037-1042.
96.
Campbell MJ, Dawson M, Koeffler HP.Growth inhibition of DU-145 prostate cancer cells by a bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide. Br J Cancer. 1998;77:739-744.
97.
Berchem GJ, Bosseler M, Sugars LY, et al.Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 1995;55:735-738.
98.
Raynaud FI, Orr RM, Goddard PM, et al.Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous infusion to mice. J Pharmacol Exp Ther. 1997;281:420-427.
99.
Cotter FE, Johnson P, Hall P, et al.Antisense oligodeoxynucleotide suppression of B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 1994;9:3049-3055.
100.
Correale P, Walmsley K, Nieroda C, et al.In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997;89:293-300.
101.
Peehl DM, Skowronski RJ, Leung K, et al.Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994;54:805-810.
102.
Hedlund TE, Moffatt KA, Miller GJ.Stable expression of the nuclear vitamin D receptor in human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1,25- dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology. 1996;137:1554-1561.
103.
Zhuang S-H, Burnstein KL.Antiproliferative effect of 1-a,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998;139:1197-1207.
104.
Myers C, LaRocca RV, Cooper MR, et al.Role of suramin in cancer biology and treatment. In: Broder S, ed. Molecular Foundations of Oncology. Baltimore: Williams & Wilkins; 1991:413-431.
105.
Moscatelli D, Quarto N.Transformation of NIH 3T3 cells with basic fibroblast growth factor receptor or the hst/k-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol. 1989;109:2519-2527.
106.
Pollak M, Richard M.Suramin blockade of insulin-like growth factor I stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst. 1990;82:1349-1352.
107.
Wilding G, Zugmeier G, Knabbe C, et al.The role of transforming growth factors a and b in human prostate cancer cell growth. Proc Am Assoc Cancer Res. 1988;29:241-241.
108.
Hosang M.Suramin binds to platelet-derived growth factor and inhibits biological activity. J Cell Biochem. 1985;29:265-273.
109.
Myers C, Cooper M, Stein C, et al.Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992;10:881-889.
110.
Small EJ, Marshall ME, Reyno L, et al.Superiority of suramin plus hydrocortisone over placebo plus hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol. 1998; 17:1187-1187.
111.
Stark MJ, Burke YD, McKinzie JH, et al.Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett. 1995;96:15-21.
112.
Reddy BS, Wang CX, Samaha H, et al.Chemoprevention of colon carcinoma by dietary perillyl alcohol. Cancer Res. 1997;57:420-425.
113.
Gould MN.Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem. 1995;22:139-144.
114.
Shi W, Gould MN.Differentiation of neuro-2a cells induced by the monoterpene, perillyl alcohol. Proc Am Assoc Cancer Res. 1993;34:3264-3264.
115.
Stayrook KR, McKinzie, Burke YD, et al.Induction of apoptosis-promoting BAK by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcino-genesis. 1997;18:1655-1668.
116.
Jirtle RL, Haag JD, Ariazi EZ, et al.Increased mannose 6-phos-phate/insulin-like growth factor II receptor and transforming growth factor b1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. 1993;53:3849-3852.
117.
Jeffers L, Church D, Gould M, et al.The effect of perillyl alcohol on the proliferation of human prostatic cell lines. Proc Am Assoc Cancer Res. 1995;36:1800-1800.
118.
Omer CA, Anthony NJ, Buser-Doepner CA, et al.Farnesyl: protein transferase inhibitors as agents to inhibit tumor growth. Biofactors. 1997;6:359-366.
